Abstract 1927P
Background
Approximately 15% of metastatic DTC will become RR, with a substantial impact on its prognosis. Although the majority of pts with RR-DTC initially achieve disease control with TKI, most will eventually develop treatment resistance and disease progression. AL2846, a multikinase inhibitor, mediate tumor growth and angiogenesis inluding VEGFR, AxL, c-MET, may lead to improved efficacy of pts with RR-DTC treated with prior TKI.
Methods
This multi-center, open-label, phase Ib study enrolled RR-DTC pts treaed with prior TKI therapy. Eligible pts received oral 90mg or 120mg of AL2846 capsules, once daily. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS) and safety.
Results
From 16 Feb 2023 to 31 Mar 2024, total 28 pts (90mg, n=17; 120mg, n=11) were enrolled in this study, with 27 pts (96%) remaining on treatment. 20 pts were papillary carcinoma, 8 pts were follicular carcinoma. All pts had progressed following 1 or 2 prior VEGFR-targeted therapy, about 22% patients received 2 lines of prior therapy. Among the 28 pts, 21 were efficacy evaluable, 7 have not reached the first evaluation. 2 pts achieved partial response (PR), while 19 pts had stable disease (SD) at best response, 11 pts had SD more than 16 weeks. DCR was 100% (21/21). The most common (>20%) treatment-emergent adverse events (TEAE) included AST/ALT increased, hypocalcemia, hypertension, elevated lactic dehydrogenase (LDH), hypercholesterolemia, hand-foot syndrome (HFS). TEAE ≥ grade 3 occurred in 5% of pts, only 1 patient had serious adverse event (SAE) of nephrotic syndrome. 4 pts led to dose reduction of AL2846 mainly due to HFS, proteinuria and oral mucositis. Interestingly, 1 patient achieved tumor shrinkage after dose-upregulation to 120mg during treatment, and was well tolerated.
Conclusions
AL2846 demonstrated a well-tolerated safety profile and a promising antitumor activity in previously TKI treated RR-DTC pts, which warrants further clinical evaluation.
Clinical trial identification
NCT05745363.
Editorial acknowledgement
Legal entity responsible for the study
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1524P - Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
Presenter: Vincent Chung
Session: Poster session 18
Resources:
Abstract
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
Resources:
Abstract
1526P - Anti-PD-L1/TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine in previously untreated patients with locally advanced or metastatic pancreatic cancer: A multicenter, phase Ib/II study
Presenter: Jiajia Yuan
Session: Poster session 18
Resources:
Abstract
1527P - GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Presenter: Satoshi Kobayashi
Session: Poster session 18
Resources:
Abstract
1528P - TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Presenter: Yung-yeh Su
Session: Poster session 18
Resources:
Abstract
1529P - Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study
Presenter: Miaoyan Wei
Session: Poster session 18
Resources:
Abstract
1530P - Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2 positive locally advanced unresectable or metastaticpancreatic cancer.
Presenter: Funan Liu
Session: Poster session 18
Resources:
Abstract
1531TiP - TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Presenter: Michael Overman
Session: Poster session 18
Resources:
Abstract
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
Resources:
Abstract
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18
Resources:
Abstract